Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | May 21, 2026 | May 26, 2026 |
| InspireMD, Inc.NSPR · Entity 7318 | Director | January 14, 2026 | January 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,209 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 32,209 F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
InspireMD, Inc.
Report date January 14, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,047 |
Reported balance
After 2026-01-14 transaction · row 1
1 source rowRow 1 · 2026-01-14 · Grant · Acquired 44,030 · Balance 102,047 F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock represent shares of restricted stock that shall vest on January 14, 2027 (the "One Year Grant Anniversary Date"), subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Axonics, Inc.
Report date September 29, 2023 · Filed October 03, 2023
Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,777 |
Ending reported balance
After 2023-09-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-29 · Exercise / conversion · Acquired 11,250 · Balance 31,452 Row 2 · 2023-09-29 · Sale · Disposed 7,675 · Balance 23,777 F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-09-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-09-29 · Exercise / conversion · Disposed 11,250 · Balance 0 F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein.
F2: This transaction was executed in multiple trades at prices ranging from $56.51 to $57.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2023. The units represented here are pro-rated through the date of separation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 3, 2022 19:45 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 7,846 | $57.40 | $450,321.17 |
DisclosureSEC source: 0001562180-22-002348 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,218 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $56.84 to $57.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:45 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 1,500 | $56.32 | $84,474.90 |
DisclosureSEC source: 0001562180-22-002348 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,064 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $55.82 to $56.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 12,329 | $25.82 | $318,334.78 |
DisclosureSEC source: 0001562180-22-002348 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 20:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Options (Right to buy) · Derivative | 3,579 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001562180-22-002063 · primarydocument.xml · derivative · entry 5 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock · 3,579 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 1, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 20:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Options (Right to buy) · Derivative | 6,421 | $0.00 Strike: $25.82 | $0.00 |
DisclosureSEC source: 0001562180-22-002063 · primarydocument.xml · derivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,672 Underlying: Common Stock · 6,421 shares Expires 2029-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on December 12, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on December 1, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 20:13 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 10,000 | $57.00 | $570,000.00 |
DisclosureSEC source: 0001562180-22-002063 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,235 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 20:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 3,579 | $14.19 | $50,786.01 |
DisclosureSEC source: 0001562180-22-002063 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 20:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 6,421 | $25.82 | $165,790.22 |
DisclosureSEC source: 0001562180-22-002063 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 26,086 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · derivative · entry 14 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021. F13 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021. F13 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending December 31, 2021, and provided the reporting person remains in continuous service through December 31, 2021. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 10,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · derivative · entry 13 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. F12 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. F12 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2021 and provided the reporting person remains in continuous service through January 31, 2022. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 947 | $49.03 | $46,435.86 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 9 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,235 F6 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F8 · price: This transaction was executed in multiple trades at prices ranging from $48.78 to $49.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 17,737 | $48.21 | $855,106.09 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 8 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,182 F6 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F7 · price: This transaction was executed in multiple trades at prices ranging from $47.76 to $48.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 36,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 7 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2022 Filed Oct 3, 2023 19:32 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 947 | $49.03 | $46,435.86 |
DisclosureSEC source: 0001562180-23-007189 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,235 F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.78 to $49.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This amendment is being filed to address an error in reporting the amount of securities beneficially owned following reported transactions on February 3, 2022. Accordingly, this amendment is being filed to amend and restate this line from the Original Form 4 in its entirety. This Form 4 acts as an amendment for all subsequently filed Form 4s. Read SEC document |
| February 03, 2022 Filed Oct 3, 2023 19:32 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 17,737 | $48.21 | $855,106.09 |
DisclosureSEC source: 0001562180-23-007189 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,182 F2 · kind: Shares of Issuer's common stock sold to cover the reporting person's tax obligation in connection with the conversion of the Performance-Based Restricted Stock Units disclosed herein. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.76 to $48.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: This amendment is being filed to address an error in reporting the amount of securities beneficially owned following reported transactions on February 3, 2022. Accordingly, this amendment is being filed to amend and restate this line from the Original Form 4 in its entirety. This Form 4 acts as an amendment for all subsequently filed Form 4s. Read SEC document |
| February 03, 2022 Filed Oct 3, 2023 19:32 UTC Amendment | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 36,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-007189 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This amendment is being filed to address an error in reporting the amount of securities beneficially owned following reported transactions on February 3, 2022. Accordingly, this amendment is being filed to amend and restate this line from the Original Form 4 in its entirety. This Form 4 acts as an amendment for all subsequently filed Form 4s. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · derivative · entry 10 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,468 Underlying: Common Stock · 20,000 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 400 | $49.70 | $19,878.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 5 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.66 to $49.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 13,853 | $49.07 | $679,718.22 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.66 to $49.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 3,730 | $48.26 | $179,999.36 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,253 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.66 to $48.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 2,017 | $46.83 | $94,452.08 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,983 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.475 to $47.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 20,000 | $14.19 | $283,800.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · derivative · entry 12 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires not disclosed F11 · security: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024. F11 · derivative.exercise_price: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024. F11 · derivative.expiration_date: The number of Performance-Based Restricted Stock Units represents the target number of Performance-Based Restricted Stock Units that were granted to the reporting person on the date of grant, each of which represents the contingent right to receive one share of common stock, subject to the conditions set forth in the award agreement. Per the terms of the award agreement governing the Performance-Based Restricted Stock Units, the number of Performance-Based Restricted Stock Units to which the reporting person may ultimately become entitled ranges from 0% to 200% of the target number of Performance-Based Restricted Stock Units granted, based upon the total shareholder return of the Issuer's common stock relative to its peer group index over a performance period consisting of the two fiscal years ending January 31, 2024, and provided the reporting person remains in continuous service through January 31, 2024. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantPerformance-Based Restricted Stock Units · Derivative | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · derivative · entry 11 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires not disclosed F10 · security: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. F10 · derivative.exercise_price: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. F10 · derivative.expiration_date: Each Performance-Based Restricted Stock Unit represents the contingent right to receive one share of common stock, subject to the Issuer's achievement of certain operational and performance objectives during the fiscal year ending December 31, 2022 and provided the reporting person remains in continuous service through January 31, 2023. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 21:30 UTC | Axonics, Inc. AXNX · Entity 86004 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001105 · primarydocument.xml · nonDerivative · entry 6 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,718 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · derivative · entry 10 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,718 shares Expires 2027-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 21, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 21, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,477 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · derivative · entry 9 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,444 Underlying: Common Stock · 5,477 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,805 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · derivative · entry 8 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,468 Underlying: Common Stock · 10,805 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 2,046 | $52.61 | $107,632.49 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 7 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $52.46 to $53.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 3,886 | $51.68 | $200,832.37 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 6 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,046 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $51.425 to $52.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 9,756 | $50.80 | $495,647.73 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 5 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,932 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.40 to $51.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 4,312 | $49.73 | $214,427.57 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,688 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.35 to $50.305. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 3,718 | $1.42 | $5,279.56 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 5,477 | $1.63 | $8,927.51 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 21:13 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 10,805 | $14.19 | $153,322.95 |
DisclosureSEC source: 0001562180-22-000563 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,875 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · derivative · entry 13 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,921 Underlying: Common Stock · 5,875 shares Expires 2028-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on March 30, 2018, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of March 30, 2018, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 991 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · derivative · entry 12 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,934 Underlying: Common Stock · 991 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 6,866 | $55.22 | $379,163.86 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 8 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 5,875 | $1.63 | $9,576.25 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 7 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 991 | $1.32 | $1,308.12 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 6 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,142 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · derivative · entry 11 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,925 Underlying: Common Stock · 5,142 shares Expires 2027-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 5, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 5, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,701 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · derivative · entry 10 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,616 Underlying: Common Stock · 9,701 shares Expires 2027-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on May 23, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of May 23, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,291 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · derivative · entry 9 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,273 Underlying: Common Stock · 28,291 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 24,618 | $55.05 | $1,355,134.74 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 5 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $54.855 to $55.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | SaleCommon Stock | 18,516 | $54.45 | $1,008,264.71 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 4 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,618 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.83 to $54.825. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 5,142 | $1.32 | $6,787.44 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 3 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 9,701 | $1.32 | $12,805.32 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 2 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 20:45 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionCommon Stock | 28,291 | $14.19 | $401,449.29 |
DisclosureSEC source: 0001562180-21-003716 · primarydocument.xml · nonDerivative · entry 1 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 19:50 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,103 | $0.00 Strike: $14.19 | $0.00 |
DisclosureSEC source: 0001562180-21-002932 · primarydocument.xml · derivative · entry 11 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,564 Underlying: Common Stock · 15,103 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option becomes exercisable as follows: (i) 1/4 of the total number of shares of common stock underlying the option will vest on January 30, 2020 and (ii) 1/36 of the remaining shares of common stock underlying the option will vest monthly thereafter, such that the option will fully vest on January 30, 2023, provided the reporting person remains in continuous service on each vesting date. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 19:50 UTC | Axonics, Inc. AXNX · Entity 86004 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,897 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001562180-21-002932 · primarydocument.xml · derivative · entry 10 Dearen Danny L. · CIK 0001756438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 Underlying: Common Stock · 9,897 shares Expires 2027-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting on July 21, 2017, and the remainder vesting at a rate of 1/36th per month commencing upon the one-year anniversary of July 21, 2017, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. The option is subject to an early exercise provision and is immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.